Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · IEX Real-Time Price · USD
9.80
-0.14 (-1.41%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Neumora Therapeutics Employees
Neumora Therapeutics had 124 employees as of December 31, 2023. The number of employees increased by 14 or 12.73% compared to the previous year.
Employees
124
Change (1Y)
14
Growth (1Y)
12.73%
Revenue / Employee
n/a
Profits / Employee
-$2,048,556
Market Cap
1.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124 | 14 | 12.73% |
Dec 31, 2022 | 110 | 9 | 8.91% |
Dec 31, 2021 | 101 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Alignment Healthcare | 1,536 |
Galapagos NV | 1,123 |
Supernus Pharmaceuticals | 652 |
InMode | 581 |
Mirum Pharmaceuticals | 264 |
Kura Oncology | 142 |
Keros Therapeutics | 136 |
Ligand Pharmaceuticals | 58 |
NMRA News
- 12 days ago - Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation - GlobeNewsWire
- 7 weeks ago - Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression - GlobeNewsWire
- 2 months ago - Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Neumora's early-stage schizophrenia drug study put on hold - Reuters
- 2 months ago - Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study - GlobeNewsWire
- 3 months ago - Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days - GlobeNewsWire
- 4 months ago - Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer - GlobeNewsWire